4.8 Review

Long-term albumin treatment in patients with cirrhosis and ascites

期刊

JOURNAL OF HEPATOLOGY
卷 76, 期 6, 页码 1306-1317

出版社

ELSEVIER
DOI: 10.1016/j.jhep.2022.03.005

关键词

decompensated cirrhosis; ascites; long-term albumin treatment; diseasemodifying intervention; effective albumin concentration

资金

  1. EU Horizon 2020 Programmes [634579, 731875, 847949]
  2. National Institute for Health Research Health Technology Assessment [17/67/01]
  3. Instituto de Salud Carlos III through the Plan Estatal de Investigacion Cientifica y Tecnica y de Innovacion [PI 16/00043, PI20/00579]
  4. European Regional Development Fund (FEDER)
  5. EU Horizon 20/20 Programme [731875]
  6. Agencia de Gestio d'Ajuts Universitaris i de Recerca [AGAUR- 2017- SGR -01281]
  7. National Institutes of Health Research (NIHR) [17/67/01] Funding Source: National Institutes of Health Research (NIHR)
  8. H2020 Societal Challenges Programme [634579] Funding Source: H2020 Societal Challenges Programme

向作者/读者索取更多资源

Long-term administration of albumin may be effective and safe for treating patients with cirrhosis and ascites, but further research is needed to determine the target population, optimal dose and frequency of treatment, stopping rules, and cost-effectiveness in different healthcare systems.
Although proposed for the first time several decades ago, the possibility that long-term human albumin could be effective for the treatment of patients with cirrhosis and ascites has become a topic of scientific and clinical discussion in the last decade. Long-term albumin administration represents a completely different treatment perspective compared to acute or short-term uses of albumin. Results from the ANSWER and the MACHT studies indicate that long-term albumin treatment can be effective, safe and able to modify the course of the disease provided that albumin is given at a sufficient dose and for a sufficient time to restore physiological levels and functions of the circulating molecule, which are compromised, at least partially, in patients with decompensated cirrhosis. Further clinical studies and randomised trials are warranted to confirm the clinical benefits of long-term albumin therapy. Important areas for further research include determining the precise target population, the biomarkers of response, the optimal dose and frequency of albumin infusions, the stopping rules, and the cost-effectiveness of treatment in different healthcare systems across the world, particularly in those where the logistical issues and costs related to the periodic intravenous infusions may represent an important limitation to the implementation of this innovative approach in clinical practice. In this review, we will critically analyse the available data on long-term albumin treatment, focusing on the differences that exist between studies, the controversial issues and the future perspectives. (C) 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据